IL309959A - Rapid relief of motor fluctuating episodes in Parkinson's disease - Google Patents
Rapid relief of motor fluctuating episodes in Parkinson's diseaseInfo
- Publication number
- IL309959A IL309959A IL309959A IL30995924A IL309959A IL 309959 A IL309959 A IL 309959A IL 309959 A IL309959 A IL 309959A IL 30995924 A IL30995924 A IL 30995924A IL 309959 A IL309959 A IL 309959A
- Authority
- IL
- Israel
- Prior art keywords
- levodopa
- patient
- fpd
- administration
- updrs
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title claims 4
- 206010030312 On and off phenomenon Diseases 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 20
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 20
- 229960004502 levodopa Drugs 0.000 claims 20
- 230000002685 pulmonary effect Effects 0.000 claims 5
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229940112141 dry powder inhaler Drugs 0.000 claims 2
- 239000010419 fine particle Substances 0.000 claims 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229940068196 placebo Drugs 0.000 claims 1
- 239000000902 placebo Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/034778 WO2015163840A1 (en) | 2014-04-21 | 2014-04-21 | Rapid relief of motor fluctuations in parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309959A true IL309959A (en) | 2024-03-01 |
Family
ID=54332876
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309959A IL309959A (en) | 2014-04-21 | 2014-04-21 | Rapid relief of motor fluctuating episodes in Parkinson's disease |
| IL248445A IL248445A0 (en) | 2014-04-21 | 2016-10-20 | Rapid relief of motor oscillatory episodes in Parkinson's disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL248445A IL248445A0 (en) | 2014-04-21 | 2016-10-20 | Rapid relief of motor oscillatory episodes in Parkinson's disease |
Country Status (14)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014074797A1 (en) | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
| CA3087696A1 (en) * | 2018-01-05 | 2019-07-11 | Impel Neuropharma, Inc. | Intranasal delivery of levodopa powder by precision olfactory device |
| JP2021532098A (ja) | 2018-07-19 | 2021-11-25 | インペル ニューロファーマ インコーポレイテッド | パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| JP4384503B2 (ja) * | 2002-03-20 | 2009-12-16 | アルカーメス，インコーポレイテッド | レボドパの肺送達 |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| WO2008156586A2 (en) | 2007-06-12 | 2008-12-24 | Alkermes, Inc. | Inhalation device for powdered substances |
| GB2454480A (en) * | 2007-11-07 | 2009-05-13 | Vectura Group Plc | Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders |
| RU2496494C2 (ru) * | 2008-06-30 | 2013-10-27 | Новартис Аг | КОМБИНАЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ mGluR, ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ПАРКИНСОНА |
| US8399513B2 (en) * | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
| TW201304822A (zh) * | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
| BR112015009088A2 (pt) * | 2012-10-22 | 2017-07-04 | Civitas Therapeutics Inc | formulações de levodopa para alívio rápido da doença de parkinson. |
| US8545878B1 (en) * | 2012-11-09 | 2013-10-01 | Civitas Therapeutics, Inc. | Capsules containing high doses of levodopa for pulmonary use |
-
2014
- 2014-04-21 JP JP2016563193A patent/JP2017513866A/ja active Pending
- 2014-04-21 AU AU2014391721A patent/AU2014391721B2/en active Active
- 2014-04-21 BR BR112016024502A patent/BR112016024502A8/pt not_active Application Discontinuation
- 2014-04-21 MX MX2016013741A patent/MX2016013741A/es unknown
- 2014-04-21 SG SG11201608608PA patent/SG11201608608PA/en unknown
- 2014-04-21 KR KR1020167032453A patent/KR20170008754A/ko not_active Ceased
- 2014-04-21 RU RU2016144340A patent/RU2698330C2/ru active
- 2014-04-21 IL IL309959A patent/IL309959A/en unknown
- 2014-04-21 CA CA2946165A patent/CA2946165C/en active Active
- 2014-04-21 CN CN202110185196.6A patent/CN113209055A/zh active Pending
- 2014-04-21 US US15/500,608 patent/US20170296498A1/en not_active Abandoned
- 2014-04-21 WO PCT/US2014/034778 patent/WO2015163840A1/en not_active Ceased
- 2014-04-21 KR KR1020217038097A patent/KR20210144946A/ko not_active Ceased
- 2014-04-21 EP EP21150770.2A patent/EP3831375A1/en active Pending
- 2014-04-21 EP EP14889874.5A patent/EP3134077A4/en not_active Ceased
- 2014-04-21 CN CN201480079968.6A patent/CN106659685B/zh active Active
-
2016
- 2016-10-20 IL IL248445A patent/IL248445A0/en unknown
- 2016-11-14 ZA ZA2016/07833A patent/ZA201607833B/en unknown
-
2020
- 2020-09-24 AU AU2020239754A patent/AU2020239754B2/en active Active
-
2022
- 2022-01-26 US US17/584,663 patent/US20230053976A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016024502A2 (pt) | 2017-08-15 |
| US20170296498A1 (en) | 2017-10-19 |
| JP2017513866A (ja) | 2017-06-01 |
| AU2014391721B2 (en) | 2020-07-16 |
| ZA201607833B (en) | 2018-08-29 |
| AU2020239754B2 (en) | 2022-06-23 |
| IL248445A0 (en) | 2016-12-29 |
| WO2015163840A1 (en) | 2015-10-29 |
| RU2698330C2 (ru) | 2019-08-26 |
| CA2946165A1 (en) | 2015-10-29 |
| RU2016144340A3 (cg-RX-API-DMAC7.html) | 2018-05-22 |
| KR20170008754A (ko) | 2017-01-24 |
| CN106659685A (zh) | 2017-05-10 |
| MX2016013741A (es) | 2017-04-06 |
| CA2946165C (en) | 2022-10-18 |
| KR20210144946A (ko) | 2021-11-30 |
| SG11201608608PA (en) | 2016-11-29 |
| BR112016024502A8 (pt) | 2021-06-29 |
| AU2014391721A1 (en) | 2016-11-03 |
| RU2016144340A (ru) | 2018-05-22 |
| CN113209055A (zh) | 2021-08-06 |
| US20230053976A1 (en) | 2023-02-23 |
| AU2020239754A1 (en) | 2021-01-14 |
| EP3831375A1 (en) | 2021-06-09 |
| EP3134077A1 (en) | 2017-03-01 |
| CN106659685B (zh) | 2021-02-05 |
| EP3134077A4 (en) | 2017-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2025204271A1 (en) | Microcrystalline diketopiperazine compositions and methods | |
| RU2010121827A (ru) | Композиции для лечения болезни паркинсона | |
| JP6446552B2 (ja) | 体重と体脂肪減少に用いられる組成物およびその医薬品と使用 | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2014528474A5 (cg-RX-API-DMAC7.html) | ||
| JP2011520911A5 (cg-RX-API-DMAC7.html) | ||
| JP7557185B2 (ja) | 免疫応答を調節するｇａｂａの能力の強化 | |
| EP2063865A1 (en) | Long term 24 hour intestinal administration of levodopa/carbidopa | |
| TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| US20230218531A1 (en) | Long acting opioid antagonists | |
| CN1092973C (zh) | 乳香或乳香亲脂性提取物在制备用于治疗阿尔茨海默症的药物中的用途 | |
| RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| JP2020513032A5 (cg-RX-API-DMAC7.html) | ||
| JP2016521755A5 (cg-RX-API-DMAC7.html) | ||
| JP2018527386A5 (cg-RX-API-DMAC7.html) | ||
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| IL309959A (en) | Rapid relief of motor fluctuating episodes in Parkinson's disease | |
| WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir | |
| JP2016505050A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512247A5 (cg-RX-API-DMAC7.html) | ||
| WO2011014009A3 (ko) | 신규 이치환된 페녹시아세틸계 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물 | |
| JP5501451B2 (ja) | 咳の治療のためのテオブロミン | |
| JP2016520114A5 (cg-RX-API-DMAC7.html) | ||
| JP2017513866A5 (cg-RX-API-DMAC7.html) |